Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Macy's announced a quarterly dividend

10/30/23 M

TRK reported for 9 months of 2023 by RAS

10/27/23 TORS

ZIL reported for 9 months of 2023 by RAS

10/27/23 ZILL

Mostotrest reported for 9 months of 2023 by RAS

10/27/23 MSTT

DZRD reported for 9 months of 2023 by RAS

10/27/23 DZRD

Krasnoyarskenergosbyt reported for 9 months of 2023 by RAS

10/27/23 KRSB

Nornickel reported for 9 months of 2023 by RAS

10/27/23 GMKN

OGK-2 reported for 9 months of 2023 by RAS

10/27/23 OGKB

RusHydro reported for 9 months of 2023 by RAS

10/27/23 HYDR

Magnit buys 33% of Samberi chain

10/27/23 MGNT